Ваша жизнь в ваших руках. Как понять, победить и предотвратить рак груди и яичников

41. Shen, WH. and others, 1998. Stability and distribution of orally administered epidermal growth factor in neonatal pigs. Life Sciences, 63 (10), 809–820; Rao, R.K. and others, 1998. Bovine milk inhibits proteolytic degradation of epidermal growth factor in human gastric and duodenal lumen. Peptides, 19 (3), 495–504; McCuskey, R.S. and others, 1997. Effect of milk-borne epidermal growth factor on the hepatic microcirculation and Kupfer cell function in suckling rats. Biology of the Neonate, 7 (3), 202–206; Oguchi, S. and others, 1997. Growth factors in breast milk and their effect on gastrointestinal development. Chang Hua Min Kuo Hsiao Ehr Ко I Hsuek Tsa Chih, 38 (5), 332–337.

42. Salomon, D.S. and others, 1999. Cripto: a novel epidermal growth factor (EGF)-related peptide in mammary gland development and neoplasia. Bioessays, 21 (1), 61–70; Chou, YC. and others, 1999. Induction of mammary carcinomas by N-meth-yl-N-nitrosurea in ovariectomized rats treated with epidermal growth factor. Carcinogenesis, 20 (4), 677–684; Kurtz, A. and

others, 1998. Local control of mammary gland differentiation: mammary-derived growth inhibitor and pleiotrophin. Biochemical Society Symposium, 63, 51–69; Taylor, M.R. and others, 1997. Lactadherin (formerly BA46); a membrane-associat-ed gycoprotein expressed in human milk and breast carcinomas, promotes Arg-Gly-Asp (RGD)-dependent cell adhesion. DNA and Cell Biology, 16 (7), 861–869.

43. Zhau, H.J. and others, 1996. Androgen-depressed phenotype in human prostate cancer. Proc. Natl. Acad. Sei. U.S.A., 93 (26), 15 152-15 157.

44. Thornburg, W. and others, 1984. Gastrointestinal absorption of epidermal growth factor in suckling rats. American Journal of Physiology, 246, G80—G85.

45. www.prostatepointers.org/cmyers/pf0696.html

46. Gaull, G.E. and others, 1985. Significance of growth modulators in human milk. Pediatrics, 75 (2), 142–145.

47. Delgrange, E. and others, 1997. Sex related differences in the growth of prolacrinomas: a clinical and proliferation marker study. Journal of Clinical Endocrinology and Metabolism. 82 (7), 2102–2107.

48. Vonderhaar, B.K., 1998, Prolactin: The forgotten hormone of human breast cancer. Pharmacology and Therapeutics, 79 (2), 169–178; Das, R. and others; 1996. Involvement of SHC, GRB2, SOS and RAS in prolactin signal transduction in mammary epithelial cells. Oncogene, 13 (6), 1139–1145; Mershon, J, and others, 1995. Prolactin is a local growth factor in rat mammary tumors. Endocrinology, 136 (8), 3619–3623; Ginsberg, E. and others, 1995. Prolactin secretion by human breast cancer cells. Cancer Res, 55 (12), 2591–2595; Fuh, G. and others, 1995. Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. J Biol Chem, 270 (22), 13 133-13 137.

49. Leav, I. and others, 1999. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. American Journal of Pathology, 154 (3), 863–870; Horti, J. and others, 1998. A phase 2 study of bromocriptine in patients with androgen-independent prostate cancer. Oncology Reports, 5 (4), 893–896; Franklin, R.B. and others, 1997. Prolactin regulation of mitochondrial aspartate aminotransferase and proteinkinase С Molecular and Cellular Endocrinology, 127 (1), 19–25; Janssen, T. and others, 1996. In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate. Cancer, 77 (1), 144–149; Janssen, T. and others, 1995. Organ culture of human tissue as study model of hormonal and pharmacological regulation of benign prostatic hyperplasia and of prostatic cancer, (frans) Acta Urol Belg, 63 (1), 7-14; Oliver, R.T. and others, 1995. New directions with hormone therapy in prostate cancer: possible benefit from blocking prolactin and use of hormone treatment intermittently in combination with immunotherapy. Eur J Cancer, 31A (6), 859–860; Rana, A. and others, 1995. A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate. Eur J Cancer, 31A (6), 871–875.

50. Hinuma, S. and others, 1998. A prolactin-releasing peptide in the brain. Nature, 393 (6682), 272–276.